Concizumab is a humanized monoclonal antibody against tissue factor (TF) pathway inhibitor (TFPI) that is intended for subcutaneous prophylactic treatment for persons with hemophilia A or B with or without inhibitory alloantibodies to FVIII or FIX [8–10]. This evidence concerns the gene F8 and hemophilia A.